We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently announced the launch of comprehensive asset tracking solution DeviceVue.
The solution will be used alongside the company’s proprietary pump system, Sigma Spectrum Infusion System. It will aid clinicians and biomedical engineers to quickly find unused pumps by viewing location and status data from their PC, iPad or iPhone. We are bullish on the development as it provides an edge to Sigma Spectrum when compared with other smart pumps in the market.
Stock Performance Solid
Over the past six months, Baxter has gained 30.3% comparing favorably with the broader industry’s increase of 7.6%. Moreover, the current level is higher than the S&P 500's gain of 3.9% over the same time frame.
Baxter is poised to gain from an expanding product portfolio and increasing penetration in international markets. Accretive acquisitions like these are also key catalysts for the long haul. The company’s long-term expected earnings growth rate of 10.8% holds promise in this regard.
Baxter has a diverse portfolio with improved existing products and new product development namely, more convenient kidney dialysis solutions, regenerative tissue products and the next-generation SIGMA Spectrum infusion pump. Recently, Notably, this Deerfield, IL-based company launched a new version of the AK-98 HD system. The platform offers two-way IT connectivity and capabilities to meet the needs of potential patients.
Baxter is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
The company's focus on product launches is a significant catalyst in our view. Additionally, its expansion plans, especially in emerging overseas markets and the acquisition-driven strategy hold considerable promise.
On the flipside, lower demand for healthcare products, intense competition, significant exposure to foreign exchange volatility and higher debt levels pose major headwinds.
SONOVA represented a solid return of 28.9% over the last year. The company has a long-term expected earnings growth rate of 7%.
IDEXX Laboratories has an average earnings beat of 9.3% over the trailing four quarters. It has a long-term expected earnings growth rate of 19.8%.
Cogentix Medical came up with a positive earnings surprise of 200% in the last quarter. The stock represented a stellar return of 100.9% in the last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Baxter Announces Launch of DeviceVue System for Sigma Pumps
Baxter International Inc. (BAX - Free Report) recently announced the launch of comprehensive asset tracking solution DeviceVue.
The solution will be used alongside the company’s proprietary pump system, Sigma Spectrum Infusion System. It will aid clinicians and biomedical engineers to quickly find unused pumps by viewing location and status data from their PC, iPad or iPhone. We are bullish on the development as it provides an edge to Sigma Spectrum when compared with other smart pumps in the market.
Stock Performance Solid
Over the past six months, Baxter has gained 30.3% comparing favorably with the broader industry’s increase of 7.6%. Moreover, the current level is higher than the S&P 500's gain of 3.9% over the same time frame.
Baxter is poised to gain from an expanding product portfolio and increasing penetration in international markets. Accretive acquisitions like these are also key catalysts for the long haul. The company’s long-term expected earnings growth rate of 10.8% holds promise in this regard.
Baxter has a diverse portfolio with improved existing products and new product development namely, more convenient kidney dialysis solutions, regenerative tissue products and the next-generation SIGMA Spectrum infusion pump. Recently, Notably, this Deerfield, IL-based company launched a new version of the AK-98 HD system. The platform offers two-way IT connectivity and capabilities to meet the needs of potential patients.
Baxter is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
The company's focus on product launches is a significant catalyst in our view. Additionally, its expansion plans, especially in emerging overseas markets and the acquisition-driven strategy hold considerable promise.
On the flipside, lower demand for healthcare products, intense competition, significant exposure to foreign exchange volatility and higher debt levels pose major headwinds.
Zacks Rank & Stocks to Consider
Baxter has a Zacks Rank #3 (Hold). Better-ranked medical stocks include SONOVA HOLDING (SONVY - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cogentix Medical, Inc. (CGNT - Free Report) . All the companies hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
SONOVA represented a solid return of 28.9% over the last year. The company has a long-term expected earnings growth rate of 7%.
IDEXX Laboratories has an average earnings beat of 9.3% over the trailing four quarters. It has a long-term expected earnings growth rate of 19.8%.
Cogentix Medical came up with a positive earnings surprise of 200% in the last quarter. The stock represented a stellar return of 100.9% in the last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>